Galectin-1 (Gal-1) has been identified as a PET imaging biomarker that predicts tumor responses to immune checkpoint blockade therapy, aiding in patient stratification and optimizing immunotherapy, with research published in The Journal of Nuclear Medicine revealing its potential for personalized cancer treatment.